RT Conference Proceedings
T1 Canakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
A1 Paz-Ares, L.
A1 Goto, Y.
A1 Lim, W. D. T.
A1 Halmos, B.
A1 Cho, B. C.
A1 Dols, M. Cobo
A1 Gonzalez-Larriba, J. L.
A1 Zhou, C.
A1 Demedts, I.
A1 Atmaca, A.
A1 Baka, S.
A1 Mookerjee, B. P.
A1 Portella, S.
A1 Zhu, Z.
A1 Dharan, B.
A1 Reck, M.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/24516
UL https://hdl.handle.net/10668/24516
LA en
DS RISalud
RD Apr 17, 2025